UDTR Global Radar

UDTR Global Rights of Nature Radar

Documentary registry of records detected across the scholarly, legal and institutional infrastructures monitored by UDTR.

A global documentary infrastructure designed to achieve the broadest verifiable and scientifically defensible coverage of the Rights of Nature.

← Back to Radar

Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases

Identification

Public canonical key
radar:r-84d1a9d9a6f492ef636802dfa042369b
Authors
Ning Huang · Liming Wang · Hongming Deng · Chenyang Nan · Zhenbang Ye · Changchun Zhou · Jiajun Zhang · Ruoyu Zhang · Ke Xu · Jianxiong Wu · Rui Liu · Mei Liu
Reported year
2026
Reported language
en
Source type
article
First detected
2026-11-14T02:13:03.394657+00:00
Last metadata observation
2026-11-14T02:13:03.394657+00:00
Last HTTP verification
Not checked

Institutions reported by the source

Chinese Academy of Medical Sciences & Peking Union Medical College · Cancer Hospital of Chinese Academy of Medical Sciences · State Key Laboratory of Molecular Oncology · Shandong Tumor Hospital · Shandong First Medical University · Tianjin Medical University Cancer Institute and Hospital · Tianjin Medical University

Reported affiliation countries

CN

Documentary abstract — original language

Abstract Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide, and liver metastases stands as a leading contributor to its high mortality rate in advanced stages. Regorafenib plus anti-PD-1 is a new therapeutic option for patients with colorectal cancer liver metastases (CRCLM). However, a considerable number of patients have not benefited from it. In this study, KRAS mutation was identified associated with resistance to regorafenib plus anti-PD-1 in CRCLM. Dihydroartemisinin (DHA), a clinically approved anti-malaria agent, was verified to selectively downregulate KRAS G12D mutant with no discernible influences on wild-type KRAS, which is consistent with the higher sensitivity of KRAS -mutant CRC cells and organoids to DHA treatment. In preclinical KRAS G12D CRCLM models, DHA substantially potentiated the therapeutic efficacy of regorafenib plus anti-PD-1 by remodeling the tumor immune microenvironment, including enhancing the cytotoxicity of CD8 + effector T cells and promoting pro-inflammatory macrophage polarization. Mechanically, DHA could restore interferon response that was impaired by oncogenic KRAS mutations, and inhibit ERBB signaling activation induced by regorafenib. Collectively, these findings support DHA as a potential adjunct to regorafenib plus anti-PD-1 for KRAS G12D CRCLM and suggest a therapeutic strategy with translational potential for KRAS -driven malignancies.

Identifiers

OPENALEX
https://openalex.org/W7167412604
DOI
10.1038/s41419-026-09042-z
PMID
https://pubmed.ncbi.nlm.nih.gov/42402611
PMCID
https://www.ncbi.nlm.nih.gov/pmc/articles/13612556

Documentary context

Documentary family
article
Source-reported types
article
Publishers
Springer Nature

Entity mentions are not evidence of legal recognition. Jurisdiction studied is separate from author affiliation country.

Sources

OpenAlex · Record 1

Cite this reference

Ning Huang; Liming Wang; Hongming Deng; Chenyang Nan; Zhenbang Ye; Changchun Zhou; Jiajun Zhang; Ruoyu Zhang; Ke Xu; Jianxiong Wu; Rui Liu; Mei Liu. Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases. 2026. https://doi.org/10.1038/s41419-026-09042-z

JSON · CSL-JSON · BibTeX · RIS · CSV · JSON-LD ·

APA, Chicago, ISO 690: bibliographic formats using available fields. OSCOLA / Bluebook: structured data only; full legal citation compliance is not claimed without verification of required elements.

APA
Ning Huang; Liming Wang; Hongming Deng; Chenyang Nan; Zhenbang Ye; Changchun Zhou; Jiajun Zhang; Ruoyu Zhang; Ke Xu; Jianxiong Wu; Rui Liu; Mei Liu. (2026). Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases. https://doi.org/10.1038/s41419-026-09042-z
Chicago
Ning Huang; Liming Wang; Hongming Deng; Chenyang Nan; Zhenbang Ye; Changchun Zhou; Jiajun Zhang; Ruoyu Zhang; Ke Xu; Jianxiong Wu; Rui Liu; Mei Liu. Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases. 2026. https://doi.org/10.1038/s41419-026-09042-z
ISO 690
Ning Huang; Liming Wang; Hongming Deng; Chenyang Nan; Zhenbang Ye; Changchun Zhou; Jiajun Zhang; Ruoyu Zhang; Ke Xu; Jianxiong Wu; Rui Liu; Mei Liu. Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases. 2026. https://doi.org/10.1038/s41419-026-09042-z

Warning: Undefined array key "last_link_verified" in /home/clients/e27d81e12f04d2bfd747aa264540ac56/sites/_UDTR_APP/legal_library_reference.php on line 31

UDTR Global Rights of Nature Legal Library. Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases. Documentary record: https://www.declarationuniverselledesdroitsdelarbre.org/global-rights-of-nature-radar/reference/r-84d1a9d9a6f492ef636802dfa042369b/ · Last HTTP verification: not performed

Report a correction

Frozen-version metadata

Research dossiers and documentary relations

Source roles

Bibliographic / original publication source · https://doi.org/10.1038/s41419-026-09042-z

An authority link alone does not verify a legal claim. Abstracts and full texts remain subject to their source terms.

Documentary status

Relevance pending

Library

This identity is not yet included in the Legal Library.

UDTR Global Rights of Nature Legal Library